Covestor LTD Catalyst Pharmaceuticals, Inc. Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Covestor LTD holds 531 shares of CPRX stock, worth $11,405. This represents 0.01% of its overall portfolio holdings.

Number of Shares

531

Previous 776 31.57%

Holding current value

$11,405

Previous $12,000 8.33%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$15.19 - $21.35 $3,721 - $5,230	-245 Reduced 31.57%	531 $11,000
Q2 2024 Aug 09, 2024	BUY	$14.68 - $16.92 $117 - $135	8 Added 1.04%	776 $12,000
Q1 2024 May 10, 2024	BUY	$13.18 - $17.11 $843 - $1,095	64 Added 9.09%	768 $12,000
Q4 2023 Feb 09, 2024	BUY	$11.78 - $17.29 $1,390 - $2,040	118 Added 20.14%	704 $12,000
Q3 2023 Nov 13, 2023	SELL	$11.69 - $15.02 $1,005 - $1,291	-86 Reduced 12.8%	586 $7,000
Q2 2023 Aug 11, 2023	SELL	$11.5 - $18.08 $18,756 - $29,488	-1,631 Reduced 70.82%	672 $9,000
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $1,534 - $2,252	107 Added 4.87%	2,303 $38,000
Q4 2022 Feb 13, 2023	SELL	$12.25 - $19.5 $661 - $1,053	-54 Reduced 2.4%	2,196 $40,000
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $16,096 - $35,385	-2,280 Reduced 50.33%	2,250 $29,000
Q2 2022 Aug 10, 2022	SELL	$6.23 - $8.57 $2,168 - $2,982	-348 Reduced 7.13%	4,530 $32,000
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $22,917 - $35,865	4,316 Added 767.97%	4,878 $40,000
Q4 2021 Feb 10, 2022	BUY	$5.21 - $7.45 $2,928 - $4,186	562 New	562 $4,000

Others Institutions Holding CPRX

# of Institutions

327

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.21B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account